American Trust Lowers Stock Holdings in Becton, Dickinson and Company (NYSE:BDX)

American Trust cut its stake in Becton, Dickinson and Company (NYSE:BDXGet Rating) by 2.6% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,780 shares of the medical instruments supplier’s stock after selling 74 shares during the period. American Trust’s holdings in Becton, Dickinson and were worth $739,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Icapital Wealth LLC purchased a new position in Becton, Dickinson and in the first quarter valued at $31,000. Disciplined Investments LLC purchased a new stake in Becton, Dickinson and during the 1st quarter worth about $32,000. Rosenberg Matthew Hamilton lifted its holdings in Becton, Dickinson and by 61.5% during the 1st quarter. Rosenberg Matthew Hamilton now owns 126 shares of the medical instruments supplier’s stock worth $34,000 after buying an additional 48 shares during the last quarter. Core Alternative Capital lifted its holdings in Becton, Dickinson and by 688.2% during the 1st quarter. Core Alternative Capital now owns 134 shares of the medical instruments supplier’s stock worth $36,000 after buying an additional 117 shares during the last quarter. Finally, McIlrath & Eck LLC lifted its holdings in Becton, Dickinson and by 44.9% during the 1st quarter. McIlrath & Eck LLC now owns 142 shares of the medical instruments supplier’s stock worth $38,000 after buying an additional 44 shares during the last quarter. 86.74% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts have issued reports on BDX shares. The Goldman Sachs Group lifted their price target on Becton, Dickinson and from $278.00 to $319.00 and gave the stock a “buy” rating in a report on Tuesday, August 16th. Citigroup downgraded Becton, Dickinson and from a “neutral” rating to a “sell” rating and decreased their price target for the stock from $265.00 to $235.00 in a report on Monday, July 11th. Stifel Nicolaus decreased their price target on Becton, Dickinson and from $290.00 to $280.00 in a report on Monday, July 18th. Morgan Stanley cut their target price on Becton, Dickinson and from $282.00 to $272.00 and set an “overweight” rating on the stock in a research report on Friday, July 15th. Finally, StockNews.com raised Becton, Dickinson and from a “hold” rating to a “buy” rating in a report on Saturday, September 10th. One analyst has rated the stock with a sell rating, three have issued a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat, Becton, Dickinson and presently has an average rating of “Hold” and an average price target of $277.63.

Insider Buying and Selling at Becton, Dickinson and

In other Becton, Dickinson and news, CEO Thomas E. Polen, Jr. sold 9,500 shares of the company’s stock in a transaction that occurred on Monday, August 15th. The stock was sold at an average price of $265.13, for a total transaction of $2,518,735.00. Following the completion of the sale, the chief executive officer now directly owns 28,878 shares of the company’s stock, valued at approximately $7,656,424.14. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other news, CEO Thomas E. Polen, Jr. sold 9,500 shares of the stock in a transaction that occurred on Monday, August 15th. The stock was sold at an average price of $265.13, for a total transaction of $2,518,735.00. Following the completion of the transaction, the chief executive officer now directly owns 28,878 shares of the company’s stock, valued at approximately $7,656,424.14. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, EVP Samrat S. Khichi sold 9,185 shares of the stock in a transaction that occurred on Tuesday, August 9th. The stock was sold at an average price of $260.44, for a total value of $2,392,141.40. Following the transaction, the executive vice president now directly owns 5,928 shares of the company’s stock, valued at $1,543,888.32. The disclosure for this sale can be found here. Insiders sold a total of 19,160 shares of company stock valued at $5,036,751 in the last ninety days. Insiders own 0.50% of the company’s stock.

Becton, Dickinson and Stock Down 0.9 %

Becton, Dickinson and stock opened at $254.32 on Friday. Becton, Dickinson and Company has a fifty-two week low of $231.46 and a fifty-two week high of $280.62. The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.90 and a current ratio of 1.35. The company has a market capitalization of $72.53 billion, a P/E ratio of 43.85, a PEG ratio of 3.39 and a beta of 0.57. The stock has a 50-day simple moving average of $251.79 and a 200-day simple moving average of $254.93.

Becton, Dickinson and (NYSE:BDXGet Rating) last posted its quarterly earnings data on Thursday, August 4th. The medical instruments supplier reported $2.66 EPS for the quarter, beating the consensus estimate of $2.50 by $0.16. The firm had revenue of $4.64 billion during the quarter, compared to the consensus estimate of $4.47 billion. Becton, Dickinson and had a return on equity of 14.55% and a net margin of 8.88%. The firm’s revenue was down 5.1% compared to the same quarter last year. During the same period in the prior year, the business earned $2.74 EPS. Equities research analysts expect that Becton, Dickinson and Company will post 11.31 earnings per share for the current year.

Becton, Dickinson and Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 30th. Shareholders of record on Friday, September 9th will be paid a dividend of $0.87 per share. This represents a $3.48 annualized dividend and a yield of 1.37%. The ex-dividend date of this dividend is Thursday, September 8th. Becton, Dickinson and’s dividend payout ratio is presently 60.00%.

About Becton, Dickinson and

(Get Rating)

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems.

Featured Articles

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.